Patient and transplantation characteristics
| Characteristic, n (%) . | MMF (n = 74) . | Placebo (n = 77) . |
|---|---|---|
| Age 50 y or older | 40 (54) | 42 (55) |
| Male patient | 41 (55) | 40 (52) |
| Risk of recurrent malignancy* | ||
| Low | 50 (68) | 52 (68) |
| High | 24 (32) | 25 (32) |
| Female donor for male patient | 18 (24) | 15 (19) |
| Nonmyeloablative conditioning | 21 (28) | 26 (34) |
| Source of stem cells | ||
| Mobilized blood | 64 (86) | 63 (82) |
| Marrow | 6 (8) | 10 (13) |
| Cord blood | 4 (5) | 4 (5) |
| Donor | ||
| HLA-matched relative | 36 (49) | 41 (53) |
| HLA-matched unrelated donor | 23 (31) | 25 (32) |
| HLA-mismatched unrelated donor | 15 (20) | 11 (14) |
| Characteristic, n (%) . | MMF (n = 74) . | Placebo (n = 77) . |
|---|---|---|
| Age 50 y or older | 40 (54) | 42 (55) |
| Male patient | 41 (55) | 40 (52) |
| Risk of recurrent malignancy* | ||
| Low | 50 (68) | 52 (68) |
| High | 24 (32) | 25 (32) |
| Female donor for male patient | 18 (24) | 15 (19) |
| Nonmyeloablative conditioning | 21 (28) | 26 (34) |
| Source of stem cells | ||
| Mobilized blood | 64 (86) | 63 (82) |
| Marrow | 6 (8) | 10 (13) |
| Cord blood | 4 (5) | 4 (5) |
| Donor | ||
| HLA-matched relative | 36 (49) | 41 (53) |
| HLA-matched unrelated donor | 23 (31) | 25 (32) |
| HLA-mismatched unrelated donor | 15 (20) | 11 (14) |
Table S1 contains definitions of risk categories.